Broderick Brian C Denali Therapeutics Inc. Transaction History

Broderick Brian C

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 08, 2022	SELL	$42.59 - $55.02 $170,360 - $220,080	-4,000 Closed	0 $0
Q4 2020 Feb 16, 2021	SELL	$36.89 - $93.56 $1.92 Million - $4.87 Million	-52,000 Reduced 92.86%	4,000 $335,000
Q3 2020 Oct 28, 2020	SELL	$23.13 - $38.84 $659,366 - $1.11 Million	-28,507 Reduced 33.73%	56,000 $2.01 Million
Q2 2020 Jul 28, 2020	BUY	$16.01 - $28.82 $1.35 Million - $2.44 Million	84,507 New	84,507 $2.04 Million

227

119M

60.6K

48.4K

Ticker DNLI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 134,174,000
Market Cap $2.86B
Description
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...

Get notified when there are updates to the investment portfolio of Broderick Brian C, based on Form 13F filings with the SEC.

Stay updated on Broderick Brian C with notifications on news.